LB
FTH

Leo Brokerage’s Faeth Therapeutics FTH Stock Holding History

Leo Brokerage’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$16.9K Hold
742
– – ﹤0.01% 301
2023
Q1 		$22.3K Buy
+742
New +$22K ﹤0.01% 295
2022
Q2 		$34K Hold
742
– – 0.01% 171
2022
Q1 		$34K Buy
+742
New +$59K 0.01% 242
2021
Q3 		$156K Buy
+742
New +$135K 0.03% 178

Other funds holding FTH

NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Leo Brokerage's FTH Position: Q2 2023 in Review

Leo Brokerage held its Faeth Therapeutics (FTH) position steady in Q2 2023 at 742 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #301.

Leo Brokerage first reported a position in FTH in Q3 2021 and has held it in 5 quarters since. The position peaked at $156K in Q3 2021. 24 funds tracked by Wall St. Rank hold FTH as of Q2 2023.

  • Leo Brokerage held 742 shares of Faeth Therapeutics worth $16.9K as of Q2 2023.
  • Leo Brokerage left its Faeth Therapeutics share count unchanged in Q2 2023.
  • Faeth Therapeutics made up ﹤0.01% of Leo Brokerage's portfolio in Q2 2023, its #301 holding.
  • Leo Brokerage first reported a position in Faeth Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • Leo Brokerage's Faeth Therapeutics position peaked at $156K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2023.

Based on Leo Brokerage's 13F filing for Q2 2023, filed 25 Jul 2023.